O-87 Duration of chemotherapy and survival in advanced non-small cell lung cancer (NSCLC). A multicenter, prospective randomised study

Andresen, Olga; Sörenson, Sverre; Bergman, Bengt; Sundstrøm, Stein; Vilsvik, Jan; Aasebø, Ulf; Bremnes, Roy M.; Gilleyrd, Mona

doi:10.1016/s0169-5002(03)91745-4

Cited by 7 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At least three randomized trials have addressed this issue, and it appears that prolonging chemotherapy beyond three to four cycles adds toxicity without additional clinical benefit. 86 – 88 …”

Section: Chemotherapy For Advanced Diseasementioning

confidence: 99%

Lung Cancer

Maghfoor

Perry

2005

Annals of Saudi Medicine

View full text Add to dashboard Cite

SummaryLung cancer is the leading cause of cancer-related mortality. Since tobacco smoking is the cause in vast majority of cases, the incidence of lung cancer is expected to rise in those countries with high or rising incidence of tobacco smoking. Even though populations at risk of developing lung cancer are easily identified, mass screening for lung cancer is not supported by currently available evidence. In case of non-small cell lung cancer, a cure may be possible with surgical resection followed by post-operative chemotherapy in those diagnosed at an early stage. A small minority of patients who present with locally advanced disease may also benefit from pre-operative chemotherapy and/or radiation therapy to down stage the tumor to render is potentially operable. In a vast majority of patients, however, lung cancer presents at an advanced stage and a cure is not possible with currently available therapeutic strategies. Similarly, small cell lung cancer confined to one hemi-thorax may be curable with a combination of chemotherapy and thoracic irradiation followed by prophylactic cranial irradiation, if complete remission is achieved at the primary site. Small cell lung cancer that is spread beyond the confines of one hemi-thorax is, however, considered incurable. In this era of molecular targeted therapies, new agents are constantly undergoing pre-clinical and clinical testing with the aim of targeting the molecular pathways thought be involved in etiology and pathogenesis of lung cancer.

show abstract